drug · vaccine component
meningococcal [serotype B] vaccine
Phase 3updated 3mo agoby $GSK GSK plc🔗 ChEMBL
Phase 3community read0 votes
Vaccine component drug with a maximum clinical stage of Approval (across all indications), with an approval for meningococcal infection and meningococcal meningitis.
targets
Neisserial heparin binding antigen
all catalysts(0)
nothing on the calendar yet
Trials studying meningococcal [serotype B] vaccine
- phase1A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104
- phase3Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
- phase3Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.
- phase3Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
- phase2A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
- phase2A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
- —Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that